|
|
 |
| Scientific Program |
 |
|
|
Hall A |
|
|
|
|
08:30-10:00 |
Type 2 Diabetes- Therapeutic Quandaries I
Chairs: A. Ametov, Russia & K. Petersen, USA
Supported by an unrestricted educational grant from Sanofi |
|
08:30-08:35 |
Introduction |
|
|
08:35-08:55
08:55-09:15
09:15-09:35 |
Should we begin by replacing insulin deficiency or reducing insulin resistance?
Early insulin replacement therapy: A. Karasik, Israel
Reducing insulin resistance: G. Shulman, USA
Discussion |
|
09:35-09:55
09:55-10:00 |
Early insulinization to prevent diabetes progression
I. Raz, Israel
Discussion |
|
|
10:30-12:00 |
News on the Incretins
Chairs: B. Itzhak, Israel & F. Giorgino, Italy
Supported by an unrestricted grant from Boehringer Ingelheim / Eli Lilly |
|
10:30-10:35 |
Introduction |
|
10:35-10:55 |
New insights on the mechanisms of action of DPP-4 inhibitors
M. Nauck, Germany |
|
10:55-11:15 |
A review of the cardiac and endothelial effects of incretin therapies
F. Giorgino, Italy |
|
11:15-11:35
11:35-12:00 |
The pancreatic islet incretin system
M. Donath, Switzerland
Discussion |
|
|
13:00-15:00 |
Insulin Pump for T2D
Chair: O. Mosenzon, Israel
Supported by an unrestricted educational grant from Medtronic |
|
13:00-13:05 |
Introduction |
|
|
13:05-13:25
13:25-13:45
13:45-14:05 |
Insulin pump for T2DM:
The use of CSII in T2DM
Y. Reznik, France
The misuse of CSII in T2DM
O. Cohen, Israel
Discussion on current indications and future trends |
|
14:05-14:25
|
Insulin analogues
A. Garber, USA |
|
14:25-14:40
14:40-14:55
14:55-15:00 |
Intensification of insulin therapy in primary care:
Which is preferable - Basal Bolus or Premix?
Basal Bolus: H. Yki-Jarvinen, Finland
Premix: O. Mosenzon, Israel
Discussion |
|
|
15:30-17:00 |
Clinical Development of Glucose-Lowering Medications: Global and Regional
Chair: B. Hirshberg, USA & C. Bailey, UK |
|
15:30-15:35 |
Introduction |
|
15:35-15:55 |
What type of data will we get from these large outcome studies?
C. Bailey, UK |
|
15:55-16:15 |
Potential implications for clinical practice
S. Del Prato, Italy |
|
16:15-16:35 |
A cardiologist in the endocrine world
C. Lotan, Israel |
|
|
16:35-16:55
16:55-17:00 |
Industry perspective
B. Hirshberg, USA
Discussion |
|
Hall B |
|
|
|
|
08:30-10:00 |
New Treatment Strategies
Chairs: M. Shestakova, Russia& J. Davidson, USA |
|
08:30-08:35 |
Introduction |
|
|
08:35-08:50
08:50--09:05
09:05-09:15 |
How low should blood glucose control be?
Very low: P. Pozzilli, Italy
Not too low: E. Bonora, Italy
Discussion |
|
|
09:15-09:30
09:30-09:45
09:45-10:00 |
Individualization therapy: Fashion or fact?
Fashion: C.J. Tack, Netherlands
Fact: J. Davidson, USA
Discussion |
|
|
10:30-12:00 |
The Unsolved Problem of Hypoglycaemia
Chairs: G. Jermendy, Hungary & S. Heller, UK |
|
10:30-10:35 |
Introduction |
|
|
10:35-10:50
10:50-11:05
11:05-11:20 |
Hypoglycaemia is of similar importance for every patient
Yes: S. Heller, UK
No: M. Theodorakis, Greece
Discussion |
|
|
11:20-11:35
11:35-11:50
11:50-12:00 |
Hypoglycaemia is of cardiovascular importance
Yes: N. Lalic, Serbia
No: I. Tkáč, Slovakia
Discussion |
|
|
13:00-15:00 |
Hypertension
Chairs: Y. Yodfat, Israel & D. de Zeeuw, The Netherlands |
|
13:00-13:05 |
Discussion |
|
|
13:05-13:20
13:20-13:35 |
Should we treat proteinuria with more than one RAAS inhibitor?
Pro: M. Ravid, Israel
Con: D. de Zeeuw, The Netherlands |
|
|
13:35-13:55 |
Should albuminuria be a target of treatment in hypertension?
H. Haller, Denmark |
|
13:55-14:15 |
Reno-protection vs. cardio-protection: A clinical dilemma
M. Ravid, Israel |
|
14:15-14:35
14:35-15:00 |
New opportunities for kidney protection in diabetes
A. Solini, Italy
Discussion |
|
|
15:30-17:00 |
Lifestyle Therapies for Diabetes
Chair: M. Laakso, Finland & W. Cefalu, USA |
|
15:30-15:35 |
Introduction |
|
15:35-16:05 |
Combination of GLP1 and insulin as first-line therapy
|
|
16:05-16:45
|
Prevention of diabetes: From research to practice
W. Cefalu, USA
Discussion: Diabetes Prevention |
|
Hall C |
|
|
|
|
|
Pathophysiology of Type 2 Diabetes
Chairs: I. Tkac, Slovakia and P. Pozzilli, Italy |
|
08:30-08:35 |
Introduction |
|
08:35-08:50
08:50-09:05
|
Impaired insulin secretion in T2D
It's all beta cell mass: J. Meier, Germany
It's all beta cell function: R. Bonadonna, Italy
Discussion |
|
|
09:15-09:30
09:30-09:45
09:45-10:00 |
Genetic screening for the risk of diabetes: Valuable or worthless?
Valuable: M. Laakso, Finland
Worthless: V. Lyssenko, Sweden
Discussion |
|
|
10:30-12:00 |
Learning From the Literature
Chair: N. Katsilambros, Greece & E. Mannucci, Italy |
|
10:30-10:35 |
Discussion |
|
|
10:35-10:55
10:55-11:05 |
Meta-analysis in diabetes: Both a salvation and a danger
P. Home, UK
Discussion |
|
|
11:05-11:25
11:25-11:45
11:45-12:00 |
Is glucose control important for prevention of cardiovascular disease in diabetes?
Yes: P. Pozzilli, Italy
No: E. Mannucci, Italy
Discussion |
|
|
13:00-15:00 |
The Place of PPAR Gama Therapy in T2D
Chair: R.A. DeFronzo
Supported by an unrestricted educational grant from Takeda Pharmaceuticals International, Inc. |
|
13:00-13:05 |
Introduction |
|
13:05-13:35 |
The liver as a therapeutic target for type 2 diabetes
G. Shulman, USA |
|
13:35-14:05 |
In vivo actions of PPARs: Glycemic control, insulin sensitivity, insulin secretion
R.A. DeFronzo, USA |
|
14:05-14:35
14:35-15:00 |
Thiazolidinediones: Cardiovascular benefits far outweigh the risks
G. Schernthaner, Austria
Discussion |
|
|
15:30-17:00 |
Future Therapy for Diabetes
Chair: I. Raz, Israel
Supported by an unrestricted educational grant from Takeda Pharmaceuticals International, Inc. |
|
15:30-15:35 |
Introduction |
|
|
|
GPR40 and TAK875
Clinical/Basic science
C. Burant, USA |
|
16:15-16:45
16:45-17:00 |
11-beta hydroxysteriod dehydrogenase: a therapeutic target for diabetes management?
A. Scheen, Belgium
Discussion |
|
|
|
|
WebStudio.co.il